ImmunoGen develops and commercializes antibody-drug conjugates (ADCs) for cancer treatment. Product candidates include mirvetuximab soravtansine for platinum-resistant ovarian cancer and Pivekimab sunirine for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. IMGC936 is a co-developed ADC with MacroGenics, and IMGN151 targets folate-receptor alpha. The company has collaborations with various pharmaceutical companies.
Indicator | Value |
---|---|
PER | 100.0 |
EV/EBITDA | -31.3 |
Price/Free Cash Flow' | 100.0 |
ROIC | -134.3% |
Net Debt/EBITDA | 1.2 |